New Method Detects Mid-Sized Peptides in Doping Control Blood Samples
Background
The detection of performance-enhancing drugs in sports is a constant challenge, particularly for peptidic drugs which are often rapidly metabolized or present at low concentrations. Current anti-doping screens frequently struggle with the diverse chemical properties and varying sizes of these compounds, leaving a significant gap in detection capabilities. This study addresses the critical need for robust analytical methods capable of identifying peptidic drugs in the 2-10 kDa range within complex biological matrices like blood.
Results
The developed LC-HRMS method demonstrated exceptional analytical performance for the target peptide. The Limit of Detection (LOD) for GHRP-2 was established at 0.08 ng/mL, with a Limit of Quantification (LOQ) of 0.2 ng/mL, significantly improving upon existing methods. Recovery rates were consistently high, ranging from 88% to 96% across all tested concentrations, indicating efficient extraction. The method exhibited excellent linearity with a correlation coefficient (R²) of >0.998 and high precision, with intra-day and inter-day relative standard deviations (RSDs) both below 8%. The developed LC-HRMS method achieved a remarkable 0.08 ng/mL LOD for GHRP-2 in human blood plasma, representing a 5-fold increase in sensitivity compared to previous standard methods and significantly extending the detection window for mid-sized peptidic doping agents. Specificity was also robust, with no significant matrix interference observed (p>0.05) from endogenous blood components, ensuring reliable detection in complex biological samples.
Why It Matters
This study provides a highly sensitive and specific analytical tool that can significantly enhance anti-doping efforts by closing a critical detection gap for mid-sized peptidic drugs. The improved sensitivity means that athletes using these substances could be detected even at very low concentrations, making it harder to evade testing. This method has the potential to be rapidly implemented in accredited anti-doping laboratories worldwide, leading to fairer competition and a cleaner sport environment. Future work will involve expanding this method to screen for a broader panel of known and emerging peptidic doping agents and validating its performance in real-world athlete samples from routine doping control programs.